🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the effort against superbug strains of the bacteria, according to health experts.

A Global Public Health Issue

The sexually transmitted infection are on the rise globally, with estimates suggesting over 82 million new cases each year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the reality of rising global incidence, the spread of superbugs and the very limited treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in the same week. This drug, which is employed against UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

As per results released by a major medical journal, the new drug cured over nine in ten of uncomplicated infections. This places it at an similar efficacy with the current standard treatment, which uses an injection and a pill. The study enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have expressed hope. The availability of a one-pill regimen like this is seen as a "game-changer" for managing the epidemic. This is viewed as essential to alleviate the strain of the illness for patients and to prevent the spread of untreatable gonorrhoea around the world.